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ABSTRACT 
Background: Myocardial injury after noncardiac surgery (MINS) was defined as prognostically 
relevant myocardial injury due to ischemia that occurs during or within 30 days after noncardiac 
surgery.  Our 4 objectives were to determine the diagnostic criteria, characteristics, predictors, 
and 30-day outcomes of MINS.  
Methods: In this international prospective cohort study of 15,065 patients aged ≥45 years who 
underwent in-patient noncardiac surgery, Troponin T was measured during the first 3 
postoperative days.  Patients with a Troponin T ≥0.04 ng/mL (elevated “abnormal” laboratory 
threshold) were assessed for ischemic features (i.e., ischemic symptoms and electrocardiography 
findings).  Patients adjudicated as having a non-ischemic troponin elevation (e.g., sepsis) were 
excluded.  To establish diagnostic criteria for MINS, we used Cox regression analyses in which 
the dependent variable was 30-day mortality (260 deaths) and independent variables included 
preoperative variables, perioperative complications, and potential MINS diagnostic criteria.   
Results: An elevated troponin after noncardiac surgery, irrespective of the presence of an 
ischemic feature, independently predicted 30-day mortality.  Therefore, our diagnostic criterion 
for MINS was a peak Troponin T ≥0.03 ng/mL judged due to myocardial ischemia.  MINS was 
an independent predictor of 30-day mortality (adjusted hazard ratio, 3.87; 95% CI, 2.96-5.08) 
and had the highest population-attributable risk (34.0%, 95% CI, 26.6-41.5) of the perioperative 
complications.  Twelve hundred patients (8.0%) suffered MINS, and 58.2% of these patients 
would not have fulfilled the universal definition of myocardial infarction.  Only 15.8% of MINS 
patients experienced an ischemic symptom. 
Conclusions: Among adults undergoing noncardiac surgery, MINS is common and associated 
with substantial mortality.   
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INTRODUCTION 
Worldwide, millions of patients die annually within 30 days of noncardiac surgery;1,2 
myocardial ischemia is a frequent cause.3,4  Most noncardiac surgery studies addressing cardiac 
complications focus on perioperative myocardial infarction.5-7  The “conventional” definition 
and diagnostic criteria of myocardial infarction in the perioperative period comes from the joint 
task force (European Society of Cardiology, American College of Cardiology Foundation, 
American Heart Association, World Heart Federation) for the universal definition of myocardial 
infarction.7  This document defines myocardial infarction as myocardial necrosis in a clinical 
setting consistent with acute myocardial ischemia, and the most common diagnostic criteria 
consist of an elevated troponin value with either an ischemic symptom or an ischemic 
electrocardiographic finding.      
Emerging evidence suggests that many patients sustain myocardial injury in the 
perioperative period that will not satisfy the diagnostic criteria for myocardial infarction.8  
Nevertheless, these events portend a poor prognosis that timely and appropriate intervention 
could potentially improve.4  This suggests that a new diagnosis of Myocardial Injury after 
Noncardiac Surgery (MINS) may be useful to patients and clinicians.  Our proposed definition of 
MINS is as follows: myocardial injury caused by ischemia (that may or may not result in 
necrosis), has prognostic relevance, and occurs during or within 30 days after noncardiac 
surgery.  The definition of MINS is broader than the definition of myocardial infarction in that it 
not only includes myocardial infarction but also the other prognostically relevant perioperative 
myocardial injuries due to ischemia.  MINS does not include perioperative myocardial injury that 
is due to a documented non-ischemic etiology (e.g., pulmonary embolism, sepsis, cardioversion).  
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No study has established the diagnostic criteria, characteristics, predictors, and 30-day outcomes 
of MINS.   
The Vascular events In noncardiac Surgery patIents cOhort evaluatioN (VISION) Study 
is a large international prospective cohort study evaluating complications after noncardiac 
surgery (clinicaltrials.gov, identifier NCT00512109).  A prior publication of the VISION Study 
demonstrated that after adjustment of preoperative clinical variables (e.g., age), peak Troponin T 
(TnT) values of 0.02 µg/L, 0.03-0.29 µg/L, and >0.30 µg/L in the first 3 days after noncardiac 
surgery were independent predictors of 30-day mortality.3  These analyses established the 
prognostic relevance of troponin measurements after surgery without taking into account 
whether the troponin elevations were due to an ischemic or non-ischemic etiology.  These 
analyses did not evaluate troponin elevations that occurred beyond day 3 after surgery.  Finally, 
these analyses adjusted for only preoperative variables and did not assess for confounding 
through other perioperative complications.  For this current publication, our primary objective 
was to inform the diagnostic criteria of MINS, and our secondary objectives were to determine 
the characteristics, predictors, and 30-day outcomes of MINS.  To do this we analyzed the 
VISION data, evaluated troponin elevations until day 30 after surgery, excluded non-ischemic 
troponin elevations, and adjusted for perioperative complications.   
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MATERIALS AND METHODS 
Study Design 
We have previously described the methodology of the VISION Study.3  This is an 
ongoing international prospective cohort study of a representative sample of adults undergoing 
noncardiac surgery.  At the beginning of this study, patients had 4th generation TnT measurements 
after noncardiac surgery.  The first 15,000 patients had event rates approximately 3 times higher 
than expected.  Recognizing that we had sufficient events to address our objectives related to the 4th 
generation TnT measurements, the Operations Committee decided to subsequently monitor the 5th 
generation high-sensitivity TnT assay.  This publication is restricted to patients enrolled during the 
period of 4th generation TnT use.   
 
Patients 
Eligible patients for the VISION Study had noncardiac surgery, were ≥45 years of age, 
received a general or regional anesthetic, and underwent elective or urgent/emergency surgery 
during the day or at night, during a weekday or the weekend.  Patients were excluded who did not 
require an overnight hospital admission after surgery, who were previously enrolled in the VISION 
Study, or who declined informed consent.  Additional exclusion criteria for the MINS study were: 
patients not having a 4th generation TnT measurement after surgery; patients having a TnT 
measurement reported as <0.04 ng/mL, <0.03 ng/mL, or <0.02 ng/mL, instead of the absolute 
value; patients whose troponin elevation was adjudicated as resulting from a non-ischemic 
etiology (e.g., sepsis, pulmonary embolism, cardioversion); and patients with incomplete data for 
the preoperative predictors of 30-day mortality.   
Research personnel primarily obtained consent prior to surgery.  For those from whom 
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we could not obtain consent preoperatively (e.g., emergency case), study personnel obtained 
consent within the first 24 hours after surgery.  Eight centers used a deferred consent process for 
patients unable to provide consent (e.g., patients sedated and mechanically ventilated) and for whom 
no next-of-kin was available.3   
 
Procedures 
Trained research personnel interviewed and examined patients and reviewed charts to 
obtain information on potential preoperative predictors of major perioperative complications 
using standardized definitions.  Patients had blood collected to measure a Roche 4th generation 
Elecsys™ TnT assay 6 to 12 hours postoperatively and on the first, second, and third days after 
surgery.  Patients enrolled between 12 and 24 hours after surgery had a TnT drawn immediately, 
and testing continued as indicated in the preceding sentence.  All TnT measurements were 
analyzed at the participating hospitals, and the TnT results were reported to the attending 
physicians.   
A TnT ≥0.04 ng/mL was the laboratory threshold considered abnormal at the time the 
study began.  Therefore, we only obtained electrocardiography on patients who had a TnT ≥0.04 
ng/mL, and we only assessed these patients for ischemic symptoms.  When a patient had a TnT 
measurement ≥0.04 ng/mL, physicians were encouraged to obtain additional TnT measurements 
(to determine the peak) and electrocardiograms for several days.  If a patient developed an 
ischemic symptom at anytime during the first 30 days after surgery, physicians were encouraged 
to obtain TnT measurements and electrocardiograms.  We defined an ischemic feature as the 
presence of any ischemic symptom or ischemic electrocardiographic finding, defined in 
Supplemental digital content 1, Appendix 1. 
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Outcomes 
The primary outcome was mortality at 30 days after surgery.  Centers also reported the 
cause of death (vascular or non-vascular, definitions in Supplemental digital content 1, Appendix 
2).  Throughout patients' hospital stay, research personnel evaluated patients clinically, reviewed 
hospital charts, ensured patients had TnT measurements drawn, and documented outcome events 
(defined in Supplemental digital content 1, Appendix 3).  We contacted patients 30 days after 
surgery; if patients (or next-of-kin) indicated that they had experienced an outcome, we contacted 
their physicians to obtain documentation.   
Adjudicators evaluated all patients with an elevated troponin measurement that occurred 
anytime during the first 30 days after surgery to determine the presence of any ischemic features 
(i.e., whether a patient would have fulfilled the universal definition of myocardial infarction),7 
the presence of a non-ischemic etiology that could explain the elevated troponin measurement, 
and that the myocardial injury had occurred during or after surgery (i.e., no evidence to support it 
was due to a preoperative event).  Their decisions were used in the statistical analyses.    
 
Data Quality 
At each site, an investigator reviewed and approved all data.  Research personnel at 
participating centers submitted the case report forms and supporting documentation directly to 
the data management system (iDataFax™, coordinating center, McMaster University, Hamilton, 
Ontario, Canada).  Data monitoring in VISION consisted of central data consistency checks, 
statistical monitoring, and on-site monitoring for all centers.3   
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Statistical Analyses 
A statistical analysis plan outlining the analyses in this paper was written prior to 
undertaking the following analyses.  For our primary objective (i.e., to establish the MINS 
diagnostic criteria), we undertook Cox proportional hazards models in which the dependent 
variable was death up to 30 days after noncardiac surgery (using a time to event analysis).  In 
these models the independent variables were: 1. nine preoperative patient characteristics that a 
prior VISION analysis demonstrated were independent predictors of 30-day mortality3 (defined 
in Supplemental digital content 1, Appendix 4); 2. six time-dependent perioperative adverse 
complications, which included the outcomes sepsis and pulmonary embolus that were not 
accompanied by a TnT elevation (defined in Supplemental digital content 1, Appendix 3); and 3. 
potential MINS diagnostic criteria.  In the first model, two potential time-dependent MINS 
diagnostic criteria were evaluated (i.e., a peak TnT ≥0.04 ng/mL with 1 or more ischemic 
features and a peak TnT ≥0.04 ng/mL without an ischemic feature).  The reference group was 
patients with a TnT ≤0.01 ng/mL.  For this first model, we excluded patients with a peak TnT 
equal to 0.02 or 0.03 ng/mL, because a prior VISION analysis demonstrated that these thresholds 
were independent predictors of 30-day mortality,3 and we did not prospectively collect data to 
determine whether these patients had experienced an ischemic feature (i.e., these patients did not 
have electrocardiography and were not assessed for ischemic symptoms).   
We prespecified two potential findings that would result in different MINS diagnostic 
criteria.  First, if both a peak TnT ≥0.04 ng/mL with and without ischemic features independently 
predicted mortality, then the MINS diagnostic criteria would only require a peak TnT ≥0.04 
ng/mL that was judged as due to myocardial ischemia (i.e., no evidence of a non-ischemic 
etiology causing the TnT elevation) without requiring the presence of an ischemic feature.  If this 
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proved the case, we planned to repeat the MINS diagnostic criteria Cox proportional hazards 
model, as described in the first paragraph of the statistical analysis section, including all patients 
and adding two more potential MINS diagnostic criteria (i.e., a peak TnT= 0.02 ng/mL and a 
peak TnT= 0.03 ng/mL without knowledge of whether these patients experienced an ischemic 
feature).   
Second, if only a peak TnT ≥0.04 ng/mL with one or more ischemic features but not a 
peak TnT ≥0.04 ng/mL without an ischemic feature independently predicted mortality, then the 
MINS diagnostic criteria would require a peak TnT ≥0.04 ng/mL with an ischemic feature.  This 
result would have prompted a repeated MINS diagnostic criteria Cox proportional hazards model 
with exploration of the impact of each individual ischemic feature (e.g., chest pain) on 30-day 
mortality to determine which ischemic features should be included in the MINS diagnostic 
criteria.   
After establishing the MINS diagnostic criteria, we determined the incidence and 95% 
confidence intervals (CI) of patients fulfilling these criteria.  We repeated the initial Cox 
proportional hazards model and included MINS as a time-dependent perioperative adverse 
complication.  For this model we determined the population-attributable risk for the independent 
predictors of 30-day mortality.9,10  The population-attributable risk represents the proportion of 
all deaths potentially attributable to the relevant risk factor (e.g., MINS).  We undertook a 
sensitivity analysis restricted to patients in whom a preoperative estimated glomerular filtration 
rate (eGFR) was available, which included eGFR as a candidate independent variable.    
We compared the baseline characteristics between patients who did and did not develop 
MINS.  Across the groups proportions were compared using Fisher’s exact test and continuous 
variables using the Student’s t or Wilcoxon rank sum test, as appropriate.  A Cox proportional 
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hazards model was undertaken to determine independent predictors of MINS up to 30 days after 
surgery.  Potential independent variables in this model included 15 baseline clinical variables and 
7 types of surgeries (defined in Supplemental digital content 1, Appendix 5).  This analysis was 
restricted to patients in whom a preoperative eGFR was available.  A sensitivity analysis 
omitting eGFR included all the patients.    
Among patients who developed MINS, we determined the incidence of each individual 
ischemic feature.  This analysis was restricted to patients who had a peak TnT ≥0.04 ng/mL, 
because patients with a peak TnT=0.03 ng/mL were not assessed for ischemic features.    
We compared the cardiovascular outcomes at 30-days after surgery (defined in 
Supplemental digital content 1, Appendix 6) for patients who did and did not suffer MINS.  For 
the cardiovascular outcomes, we determined the odds ratio and 95% CI.  Using a Fisher’s exact 
test, we compared the 30-day outcomes among patients who developed MINS compared to 
patients who did not develop MINS.   
To develop a clinical risk score to predict short-term mortality among patients who 
suffered MINS, we conducted logistic regression analysis.  The dependent variable was mortality 
at 30 days, and we evaluated the following candidate independent variables: preoperative 
variables (i.e., age, sex); and characteristics of the MINS outcome (i.e., presence of individual 
ischemic symptoms, presence of individual ischemic electrocardiographic findings, location of 
the ischemic electrocardiographic finding, and peak TnT ≥0.30 ng/mL).  Our choice of candidate 
independent variables was based upon our hypotheses regarding which variables were likely to 
be most predictive and the results of prior non-operative myocardial infarction 30-day mortality 
risk prediction models.11  In this logistic regression analysis, we included only patients with peak 
TnT ≥0.04 ng/mL, because we did not know whether patients with a peak TnT=0.03 ng/mL had 
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ischemic features.  We further included the identified significant predictors in a separate model 
to determine their adjusted odds ratios.  A scoring system was developed by assigning weighted 
points to each statistically significant predictor based on their log odds ratios, and the expected 
30-day mortality risk was determined for potential risk scores using the method outlined by 
Sullivan et al.12  Bootstrapping was performed to obtain 95% confidence intervals around the 
expected 30-day mortality risk for each potential risk score.   
 For all our regression models we used forced simultaneous entry (all candidate variables 
remained in the models regardless of statistical significance).13,14  For patients that an adjudicator 
determined suffered more than one episode of MINS throughout the first 30 days after surgery, 
we evaluated only the first episode in all analyses.  We reported adjusted odds ratios (for logistic 
regression) and adjusted hazard ratios (for Cox proportional hazard regression), 95% CI, and 
associated p-values to 3 decimal places with p-values less than 0.001 reported as p<0.001.  For 
all tests, we used alpha=0.05 level of significance.  In our models, we validated the odds ratios 
and hazard ratios and their 95% CIs through bootstrapping.  For our Cox proportional hazards 
models, we assessed discrimination through evaluation of the C index, and we conducted 
sensitivity analyses in which we used frailty models to assess for center effects.  For the logistic 
regression model, we assessed collinearity using the variance inflation factor, and we considered 
variables with a variance inflation factor >10 to be collinear.15  For our logistic regression model, 
we assessed discrimination through evaluation of the area under the receiver operating 
characteristic curve, calibration with a Hosmer-Lemeshow goodness-of-fit test, and conducted 
sensitivity analysis in which we used a mixed model to adjust for potential clustering by center.   
Our sample size was based upon our model to determine the diagnostic criteria of MINS.  
We evaluated 19 variables in this model and simulation studies demonstrate that regression 
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models require 12 events per variable evaluated.16,17  Therefore, we required 228 deaths in our 
study.  All analyses were performed using SAS version 9.2 (Cary, North Carolina). 
 
Ethical Considerations and Funding Sources 
The Research Ethics Board at each site approved the protocol prior to patient recruitment.  
Funding for this study comes from over 60 grants for VISION and its substudies.   
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RESULTS 
 Figure 1 reports the patient flow.  Of the 15,065 patients included in the MINS study, 
99.7% of the patients completed the 30-day follow-up.  Patients were recruited at 12 centers in 8 
countries in North and South America, Australia, Asia, and Europe, from August 6, 2007 to 
January 11, 2011.   
 
Diagnostic Criteria of MINS (Primary Objective) 
Supplemental digital content 2, Table 1 reports the results of the initial Cox proportional 
hazards model demonstrating that a peak TnT ≥0.04 ng/mL with and separately without an 
ischemic feature were independent predictors of 30-day mortality.  The full model that explored 
all the considered diagnostic criteria for MINS demonstrated that a peak TnT ≥0.04 ng/mL with 
1 or more ischemic features (adjusted hazard ratio, 4.82; 95% CI, 3.40-6.84), a peak TnT ≥0.04 
ng/mL without an ischemic feature (adjusted hazard ratio, 3.30; 95% CI, 2.26-4.81), and a peak 
TnT=0.03 ng/mL (adjusted hazard ratio, 4.30; 95% CI, 2.68-6.91) all independently predicted 
30-day mortality (Supplemental digital content 2, Table 2).  Therefore after adjustment for 
preoperative patient characteristics and perioperative complications, a peak TnT >0.03 ng/mL 
was an independent predictor of 30-day mortality.  Based on these analyses, our diagnostic 
criterion for MINS was any peak TnT ≥0.03 ng/mL that was judged as resulting from myocardial 
ischemia (i.e., no evidence of a non-ischemic etiology causing the TnT elevation).   
 A total of 1200 patients (8.0%; 95% CI, 7.5-8.4) fulfilled the MINS diagnostic criterion.  
Table 1 reports the predictors of 30-day mortality in the model that included preoperative 
variables and perioperative adverse complications, including MINS.  Four perioperative 
complications (i.e., MINS, sepsis, stroke, and pulmonary embolus) were independent predictors 
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of 30-day mortality.  The independent prognostic factors identified in this model potentially 
explain the majority of the deaths that occurred (i.e., the total population-attributable risk was 
92.6%; 95% CI, 89.6-95.2); among the perioperative complications, MINS had the largest 
population-attributable risk (34.0%; 95% CI, 26.6-41.5).  Our 30-day mortality sensitivity 
analysis, restricted to patients for whom a preoperative eGFR was available, demonstrated that 
MINS was not confounded by eGFR (i.e., MINS remained an independent predictor of 30-day 
mortality adjusted hazard ratio, 3.66; 95% CI, 2.71-4.93) but preoperative eGFR was not an 
independent predictor of 30-day mortality, p=0.480 (Supplemental digital content 2, Table 3).      
 
Characteristics and Predictors of MINS 
Supplemental digital content 3, Figure 1 depicts that 87.1% of MINS events occurred 
within the first 2 days after surgery.  Supplemental digital content 2, Table 4 presents the 
baseline characteristics of patients who did and did not suffer MINS.  MINS patients were older, 
had more cardiovascular risk factors, and known cardiovascular disease.  Table 2 reports the 
ischemic features of patients suffering MINS of whom 84.2% (95% CI, 81.7-86.4) did not 
experience an ischemic symptom.  A total of 34.9% (95% CI, 31.9-38.0) of MINS patients had 
an ischemic electrocardiographic finding, of which T wave inversion (23.3%; 95% CI, 20.7-
26.1) and ST depression (16.4%; 95% CI, 14.1-18.9) were the most common.  Among MINS 
patients 41.8% had an ischemic feature and would have fulfilled the universal definition of 
myocardial infarction; however, 58.2% of these patients did not experience an ischemic feature 
and would therefore not have fulfilled the universal definition of myocardial infarction.   
We identified 12 independent predictors of MINS that included the following: age ≥75 
years, cardiovascular risk factors (e.g., renal insufficiency, diabetes), known cardiovascular 
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disease (e.g., peripheral vascular disease, coronary artery disease), and surgical factors (e.g., 
urgent/emergent surgery) (Table 3).  The sensitivity analysis, which included all the patients and 
did not assess eGFR as a potential independent predictor of MINS, demonstrated similar findings 
to Table 3 except that low risk surgery was no longer predictive (adjusted hazard ratio, 0.77; 
95% CI, 0.56-1.07).      
 
Prognostic Impact of MINS 
Patients with MINS were at higher risk of a nonfatal cardiac arrest (odds ratio=14.58; 
95% CI, 5.75-37.02; p<0.001), congestive heart failure (odds ratio=10.34; 95% CI, 7.99-13.37; 
p<0.001), and stroke (odds ratio=4.66; 95% CI, 2.87-7.58; p<0.001) compared to patients who 
did not suffer MINS (Table 4).  The 30-day mortality rate was 9.8% among patients who 
suffered MINS and 1.1% among patients who did not suffer MINS (OR=10.07; 95% CI, 7.84-
12.94; p<0.001).  Among the patients suffering MINS 115 died within 30 days of surgery, 
centers reported a vascular cause of death in 62 (53.9%) patients and non-vascular in 53 (46.1%). 
The composite of nonfatal cardiac arrest, nonfatal congestive heart failure, nonfatal stroke, and 
mortality occurred more frequently in patients who suffered MINS (odds ratio=9.59; 95% CI, 
7.99-11.51; p<0.001).  In those with and without an ischemic feature, 30-day mortality rates 
were 13.5% (95% CI, 10.5%-17.3%) and 7.7% (95% CI, 5.7%-10.2%), respectively.   
   
Predictors of Mortality among Patients Suffering MINS 
Age ≥75 years, ST elevation or new left bundle branch block, and anterior ischemic 
electrocardiographic findings were independent predictors of 30-day mortality among patients 
who suffered MINS (Table 5).  Our scoring system to predict 30-day mortality in patients 
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suffering MINS assigned the following points to the independent predictor of mortality: age ≥75 
years (1 point), ST elevation or new left bundle branch block (2 points), and anterior ischemic 
electrocardiographic findings (1 point).  Figure 2 presents the expected and observed risk of 30-
day mortality among the MINS patients based on the scoring system.  Patients with a score of 0, 
1, 2, 3, or 4 had expected 30-day mortality rates of 5.2% (95% CI, 3.3-7.4), 10.2% (95% CI, 6.5-
11.9), 19.0% (95% CI, 8.7-24.3), 32.5% (95%, 10.6-45.9), and 49.8% (95% CI, 12.0-65.5), 
respectively.    
The random effect (frailty) Cox models that adjusted for potential clustering-by-center 
effects produced similar results.  Each variable included in the logistic regression models 
demonstrated a variance inflation factor <10 suggesting no collinearity.  The mixed model that 
adjusted for any potential clustering by center in the logistic regression model produced similar 
results.   
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DISCUSSION 
Principal Findings 
 In this international cohort study of 15,065 patients ≥45 years of age undergoing 
noncardiac surgery, we determined that the optimal diagnostic criterion for MINS is a peak TnT 
≥0.03 ng/mL judged due to myocardial ischemia (i.e., no evidence of a non-ischemic etiology 
causing the TnT elevation).  This criterion does not require the presence of an ischemic feature.  
MINS was common (8.0%), associated with substantial mortality and cardiovascular 
complications at 30-days, and the population-attributable risk suggests that MINS explains 
34.0% of the deaths that occur in adults during the first 30 days after noncardiac surgery.   
A minority of MINS patients experienced an ischemic symptom; only 41.8% of MINS 
patients fulfilled the universal definition of myocardial infarction.  Among the 58.2% of MINS 
patients who did not experience an ischemic feature and thus would not have fulfilled the 
universal definition of myocardial infarction, 1 in 13 died within 30 days.     
 
Our Study in Relation to Other Studies 
 In a prior VISION publication, we demonstrated that the peak troponin measurement 
during the first 3 days after noncardiac surgery was an independent predictor (based on 
adjustment of only preoperative patient characteristics) of 30-day mortality.3  Our current 
publication adds important new information by focusing on troponin elevations that were 
adjudicated as resulting from myocardial ischemia, evaluating all troponin elevations until day 
30 after surgery, and taking into account potential confounding through risk adjustment of other 
perioperative complications.  This is the first study to evaluate diagnostic criteria for MINS, 
independent predictors of MINS, and predictors of mortality in patients suffering MINS.  
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LeManach et al. conducted a consecutive cohort study of 1,136 patients undergoing abdominal 
aortic surgery in which they excluded septic patients with an elevated troponin I (Dade-
Behring).18  Consistent with our findings, they demonstrated that an elevated troponin I after 
surgery was an independent predictor of in-hospital mortality.18  A limitation of this study is that 
they did not adjust for any perioperative complications (e.g., stroke).   
A multivariable analysis of data from the PeriOperative ISchemic Evaluation (POISE) 
Trial (an 8,351 patient international randomized controlled trial) that adjusted for preoperative 
factors and perioperative complications demonstrated that the highest quartile of a cardiac 
biomarker or enzyme elevation (i.e., a troponin or creatine kinase - myocardial band value ≥3.6 
times the upper limit of normal) in patients without an ischemic feature was an independent 
predictor of 30-day mortality (adjusted odds ratio, 2.54; 95% CI, 1.65-3.90).4  Although the 
foregoing POISE analysis supports our finding that an elevated troponin after surgery without an 
ischemic feature increases short-term mortality, many different troponin assays were evaluated 
and data were insufficient to determine prognostically relevant thresholds for the individual 
troponin assays. 
 
Strengths and Limitations of Our Study 
 Strengths of our study included evaluation of a large contemporary representative sample 
of adults who underwent noncardiac surgery in 5 continents with complete follow-up data on 
99.7% of the patients.  All patients underwent troponin monitoring after surgery using the same 
troponin assay, and all patients with a TnT ≥0.04 ng/mL were prospectively assessed for 
ischemic symptoms and ischemic electrocardiographic findings.  Our 30-day mortality model 
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that included MINS (based on our diagnostic criterion) demonstrated good calibration, and the 
results were consistent across centers.   
 Our study had several limitations.  We systematically monitored troponin measurements 
only until day 3 after surgery.  Therefore, after day 3, we may have missed additional MINS 
events in patients who did not experience an ischemic symptom.  The substantial decline in 
MINS events by postoperative day 3 (Supplemental digital content 3, Figure 1) suggests, 
however, that we were not likely to have missed many MINS events.  We determined the MINS 
diagnostic threshold only for the 4th generation TnT assay; thus, evaluation of other troponin 
assays will require further research.   
We did not assess patients for the presence of ischemic features if their peak TnT was 
0.03 ng/mL.  At the start of the study we did not know that patients with a TnT of 0.03 ng/mL 
had an increased risk of 30-day mortality, and we assessed patients for ischemic features only if 
they met the laboratory threshold considered abnormal (i.e., TnT ≥0.04 ng/mL).  It is possible 
that among patients with a peak TnT=0.03 ng/mL that only those patients who also had an 
ischemic feature were at increased risk of 30-day mortality.  Given that patients with a peak TnT 
≥0.04 ng/mL did not require an ischemic feature to impact 30-day mortality, we believe it is 
unlikely that a peak TnT=0.03 ng/mL requires an ischemic feature to impact mortality.  Our 
model to predict 30-day mortality in patients suffering MINS did not include patients who had a 
peak TnT=0.03 ng/mL.  Although it is possible that our model won’t predict mortality in patients 
with a TnT=0.03 ng/mL, this is unlikely given that a prior VISION publication did not 
demonstrate any difference in the risk of mortality across peak TnT values of 0.03 to 0.29 
ng/mL.3  Although experienced physicians in perioperative medicine adjudicated all elevated 
troponin measurements to ensure there was no evidence of a non-ischemic cause, it is possible 
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some non-ischemic etiologies were missed and that some events were not due to ischemic 
myocardial injury.     
 
Implications 
Most noncardiac surgery studies evaluating cardiac complications focus on perioperative 
myocardial infarction.  Our results show that focusing on this complication would result in 
missing 58.2% of the prognostically relevant perioperative myocardial ischemic events.  Based 
on these results and the rationale presented in our introduction, we advocate assessing surgical 
patients for the diagnosis of MINS.  Although no randomized controlled trial has established an 
effective treatment for patients suffering MINS, the prognosis of these patients may be 
modifiable.  The high-quality evidence for acetyl-salicylic acid and statin therapy in the non-
operative setting,19,20 and encouraging observational data from a large international perioperative 
trial (i.e., POISE) showing an association with use of these drugs and decreased 30-day mortality 
in patients who have suffered a perioperative myocardial injury,4 suggests that acetyl-salicylic 
acid and statin therapy may benefit patients who suffer MINS.   
In our study of patients ≥45 years of age undergoing noncardiac surgery, 8.0% of patients 
suffered MINS.  It is estimated that worldwide over 100 million adults ≥45 years of age undergo 
major noncardiac surgery each year.1,21  This suggests that 8 million adults may suffer MINS 
annually.  The frequency of this perioperative complication, and the associated 30-day risk of 
cardiovascular complications and mortality, highlights the urgent need for clinical trials to 
establish strategies to prevent and treat this important complication.  
A minority (15.8%) of patients suffering MINS experienced an ischemic symptom.  
Therefore, 84.2% of MINS probably would have gone undetected without systematic troponin 
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monitoring after surgery.  Consistent with our finding, the third universal definition of 
myocardial infarction consensus statement recommends monitoring perioperative troponin 
measurements in high-risk patients undergoing noncardiac surgery.7   
 
Conclusions 
 Evaluating patients for the diagnosis of MINS compared to myocardial infarction will 
allow physicians to avoid missing the majority of the patients who develop a prognostically 
relevant perioperative myocardial injury.  Among adults undergoing noncardiac surgery, MINS 
is common (8%), and 1 in 10 patients suffering MINS will die within 30 days.  Failure to 
monitor troponin measurements after noncardiac surgery will result in missing over 80% of 
MINS events.   
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